



Celgene Corporation
 Investor Relations Department
 86 Morris Avenue
 Summit, NJ 07901
 United States

Visit IR website [↗](#)
 Sign-up for e-mail alerts [↗](#)

NASDAQ: CELG

Last Trade:	130.29
Trade Time:	4:00 PM ET Aug 22, 2017
Change:	2.86 ↑ (2.244%)
Day Range	128.14 - 130.73
52-Week Range	96.93 - 139.00
Volume	2,765,398

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Our portfolio of commercial products include REVLIMID®, VIDAZA®, THALOMID®, POMALYST®/IMNOVID®, ABRAXANE®, OTEZLA®, ISTODAX® and IDHIFA®. The drug candidates in our pipeline are at various stages of preclinical and clinical development. These cand... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Aug 1, 2017
[FDA Grants Approval of IDHIFA®. the First Oral Targeted Therapy for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and an IDH2 Mutation](#)
- Jul 28, 2017
[Celgene Corporation to Webcast at Upcoming Investor Conference](#)
- Jul 27, 2017
[Celgene Reports Second Quarter 2017 Operating and Financial Results](#)
- Jul 25, 2017
[Celgene Corporation Announces Settlement of Civil Litigation](#)
- Jul 5, 2017
[Celgene Corporation Enters Into Global Strategic Immuno-Oncology Collaboration with BeiGene to Advance PD-1 Inhibitor Program for Solid Tumor Cancers](#)

Financials [\[View all \]](#)

- Feb 10, 2017
[Annual Report \(10-K\)](#)
- Apr 27, 2017
[Proxy Statement \(DEF 14A\)](#)
- Jul 27, 2017
[Quarterly Report \(10-Q\)](#)
- Apr 27, 2017
[Quarterly Report \(10-Q\)](#)
- Oct 27, 2016
[Quarterly Report \(10-Q\)](#)